,ticker,date,time,headline,neg,neu,pos,compound
0,INCY,2021-04-13,08:00AM,Incyte to Report First Quarter Financial Results,0.0,1.0,0.0,0.0
1,INCY,2021-04-09,09:55AM,Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study,0.406,0.594,0.0,-0.4767
2,INCY,2021-04-08,07:41AM,Eli Lilly-Incyte's Baricitinib Study In Hospitalized COVID-19 Patients Fails To Meet Main Goal,0.189,0.811,0.0,-0.4215
3,INCY,2021-04-08,07:01AM,Eli Lilly and Incyte say Phase 3 study of baricitinib in hospitalized COVID-19 patients failed to meet main goal,0.163,0.837,0.0,-0.5106
4,INCY,2021-04-08,06:45AM,Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients,0.0,1.0,0.0,0.0
5,INCY,2021-04-07,05:26PM,Is INCY Stock A Buy or Sell?,0.0,1.0,0.0,0.0
6,INCY,2021-04-06,04:30PM,Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis,0.11,0.89,0.0,-0.3818
7,INCY,2021-03-31,01:33PM,"Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More",0.0,1.0,0.0,0.0
8,INCY,2021-03-30,10:06AM,Incyte (INCY) Gets EU Nod for Cholangiocarcinoma Drug Pemazyre,0.0,1.0,0.0,0.0
9,INCY,2021-03-29,02:34PM,Incyte's Pemazyre Wins European Approval For Bile Duct Cancer,0.256,0.349,0.395,0.34
10,INCY,2021-03-29,12:04PM,Incyte Announces the European Commission Approval of Pemazyre® (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement,0.0,0.765,0.235,0.7717
11,INCY,2021-03-24,03:43PM,"Biotech Stock Roundup: REGN Cocktail Data Positive, INCY's Jakafi Disappoints & More",0.171,0.592,0.237,0.25
12,INCY,2021-03-23,05:13AM,"Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy",0.271,0.598,0.131,-0.7964
13,INCY,2021-03-19,09:40AM,Incyte's Jakafi failed Phase 3 clinical trial as a treatment for some severely ill COVID-19 patients,0.453,0.547,0.0,-0.8442
14,INCY,2021-03-19,08:13AM,Incyte Drug Misses Endpoint in COVID-Respiratory-Distress Trial,0.241,0.759,0.0,-0.2263
15,INCY,2021-03-19,07:46AM,"The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs",0.355,0.645,0.0,-0.8271
16,INCY,2021-03-19,07:12AM,Incyte's Ruxolitinib Fails To Beat Placebo In Improving Mortality In Critically-Ill COVID-19 Patients,0.169,0.663,0.169,0.0
17,INCY,2021-03-18,04:30PM,Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation,0.12,0.88,0.0,-0.5267
18,INCY,2021-03-17,11:48AM,Here Are 5 Undervalued Biopharma Stocks,0.0,1.0,0.0,0.0
19,INCY,2021-03-11,09:37AM,This Underperforming Biotech Is Ready to Beat the Market,0.0,0.762,0.238,0.3612
20,INCY,2021-03-11,08:00AM,Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021,0.0,0.896,0.104,0.2732
21,INCY,2021-03-04,02:47PM,"Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More",0.0,0.763,0.237,0.4767
22,INCY,2021-03-03,09:43AM,Eli Lilly/Incyte's Baricitinib Shows Benefit In Patchy Hair Loss Disorder,0.333,0.467,0.2,-0.25
23,INCY,2021-03-03,06:45AM,Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial,0.0,1.0,0.0,0.0
24,INCY,2021-02-26,03:00AM,Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC),0.0,1.0,0.0,0.0
25,INCY,2021-02-22,09:18AM,Incyte Says FDA Grants Priority Review For Eczema Cream; Street Sees 20% Upside,0.0,0.863,0.137,0.2263
26,INCY,2021-02-22,08:00AM,Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease,0.0,0.857,0.143,0.4588
27,INCY,2021-02-19,08:00AM,Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis,0.0,0.812,0.188,0.4588
28,INCY,2021-02-11,09:13AM,"The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte",0.0,1.0,0.0,0.0
29,INCY,2021-02-11,08:00AM,Incyte to Present at Upcoming Investor Conference,0.0,1.0,0.0,0.0
30,INCY,2021-02-11,03:06AM,Update: Incyte (NASDAQ:INCY) Stock Gained 14% In The Last Five Years,0.0,0.794,0.206,0.3818
31,INCY,2021-02-10,11:57AM,"Biotech Stock Roundup: Q4 Results of BMY, REGN, BIIB & Other Regulatory Updates",0.0,1.0,0.0,0.0
32,INCY,2021-02-10,10:05AM,"Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2021",0.0,0.816,0.184,0.2023
33,INCY,2021-02-09,02:00PM,What's Behind Incyte's Better-Than-Expected Q4 Earnings,0.0,1.0,0.0,0.0
34,INCY,2021-02-09,01:30PM,Incyte Corp (INCY) Q4 2020 Earnings Call Transcript,0.0,1.0,0.0,0.0
35,INCY,2021-02-09,08:45AM,Incyte (INCY) Q4 Earnings and Revenues Top Estimates,0.0,0.795,0.205,0.2023
36,INCY,2021-02-09,07:13AM,Recap: Incyte Q4 Earnings,0.0,1.0,0.0,0.0
37,INCY,2021-02-09,07:00AM,"Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs",0.0,1.0,0.0,0.0
38,INCY,2021-02-09,06:15AM,Incyte Corp. to Host Earnings Call,0.0,1.0,0.0,0.0
39,INCY,2021-02-04,10:01AM,Incyte (INCY) to Report Q4 Earnings: What's in the Cards?,0.0,1.0,0.0,0.0
40,INCY,2021-02-03,11:52AM,3 Top Growth Stocks to Buy Right Now,0.0,0.532,0.468,0.5267
41,INCY,2021-02-03,10:11AM,Tiziana (TLSA) Posts Positive Data on Nasal COVID-19 Antibody,0.0,0.69,0.31,0.5574
42,INCY,2021-02-01,10:28AM,Incyte (INCY) Gets Positive CHMP Opinion for Pemigatinib,0.0,0.66,0.34,0.5574
43,INCY,2021-01-29,01:36PM,"Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement",0.0,0.767,0.233,0.802
44,INCY,2021-01-22,01:49PM,Incyte's (INCY) BLA for Cancer Drug Accepted for Priority Review,0.303,0.552,0.145,-0.5106
45,INCY,2021-01-21,04:30PM,Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC),0.0,0.885,0.115,0.4588
46,INCY,2021-01-19,08:00AM,Incyte to Report Fourth Quarter and Year-End 2020 Financial Results,0.0,1.0,0.0,0.0
47,INCY,2021-01-13,07:25AM,"The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations",0.0,0.753,0.247,0.5574
48,INCY,2021-01-11,10:04AM,Merus (MRUS) Stock Up on FDA's Fast Track Tag for Zenocutuzumab,0.0,1.0,0.0,0.0
49,INCY,2021-01-11,08:46AM,Regeneron (REGN) Upgrade Lifts Range-Bound Biotech Stocks,0.0,1.0,0.0,0.0
50,INCY,2021-01-06,11:14AM,Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates,0.0,1.0,0.0,0.0
51,INCY,2020-12-31,08:52AM,Incyte (INCY) Partners With Cellenkos for Myelofibrosis Treatment,0.0,1.0,0.0,0.0
52,INCY,2020-12-30,02:42PM,Incyte Higher on Plan to Develop Treatment for Myelofibrosis,0.0,1.0,0.0,0.0
53,INCY,2020-12-30,07:30AM,Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804,0.0,0.758,0.242,0.4939
54,INCY,2020-12-21,03:43PM,Is INCY A Good Stock To Buy According To Hedge Funds?,0.0,0.756,0.244,0.4404
55,INCY,2020-12-15,10:37AM,Novartis' (NVS) COVID-19 Study Fails to Meet Primary Endpoint,0.259,0.741,0.0,-0.4215
56,INCY,2020-12-14,03:36PM,Is Incyte Ready for a Sustained Turn to the Upside?,0.0,0.762,0.238,0.3612
57,INCY,2020-12-14,01:15AM,Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm,0.0,1.0,0.0,0.0
58,INCY,2020-12-11,02:01PM,Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine,0.0,0.901,0.099,0.296
59,INCY,2020-12-09,08:00AM,Incyte to Present at Upcoming Investor Conference,0.0,1.0,0.0,0.0
60,INCY,2020-12-07,10:00AM,Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas,0.0,1.0,0.0,0.0
61,INCY,2020-12-07,10:00AM,Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020,0.0,1.0,0.0,0.0
62,INCY,2020-12-05,11:32AM,Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?,0.0,1.0,0.0,0.0
63,INCY,2020-12-04,12:30PM,Incyte Announces First Data from REACH3 Trial Showing Ruxolitinib (Jakafi®) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease,0.0,0.871,0.129,0.4767
64,INCY,2020-11-25,08:03AM,Frost & Sullivan Reveals Four Key Areas Driving Growth of the Global Gigabit Ethernet Testing Market,0.0,0.843,0.157,0.3818
65,INCY,2020-11-24,01:21PM,"The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer",0.0,1.0,0.0,0.0
66,INCY,2020-11-20,10:03AM,Lilly/Incyte's Olumiant Gets FDA Emergency Nod for COVID-19,0.271,0.729,0.0,-0.3818
67,INCY,2020-11-19,05:20PM,Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19,0.148,0.852,0.0,-0.3818
68,INCY,2020-11-12,10:26AM,"Incyte (INCY), Xencor and MorphoSys Ink Collaboration Deal",0.0,1.0,0.0,0.0
69,INCY,2020-11-12,08:00AM,Incyte to Present at Upcoming Investor Conference,0.0,1.0,0.0,0.0
70,INCY,2020-11-12,07:44AM,"The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal",0.45,0.55,0.0,-0.9201
71,INCY,2020-11-11,04:02PM,"Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab",0.0,1.0,0.0,0.0
72,INCY,2020-11-11,03:15AM,These 23 stocks and ETFs will benefit from the 6 most important changes for stock-market investors under Biden,0.0,0.747,0.253,0.624
73,INCY,2020-11-10,07:30AM,These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable,0.0,1.0,0.0,0.0
74,INCY,2020-11-09,08:00AM,Data from Incytes Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer 2020 Annual Meeting,0.196,0.711,0.093,-0.5106
75,INCY,2020-11-08,08:20AM,Incyte Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now,0.167,0.833,0.0,-0.296
76,INCY,2020-11-05,08:00PM,Incyte Corp (INCY) Q3 2020 Earnings Call Transcript,0.0,1.0,0.0,0.0
77,INCY,2020-11-05,04:11PM,Incyte Earnings Miss Expectations; Tightens Outlook For Top Product,0.154,0.673,0.173,0.0516
78,INCY,2020-11-05,10:12AM,"Incyte (INCY) Q3 Earnings & Sales Miss, Jakafi Demand Strong",0.25,0.484,0.266,0.296
79,INCY,2020-11-05,08:15AM,Incyte (INCY) Q3 Earnings and Revenues Miss Estimates,0.186,0.814,0.0,-0.1531
80,INCY,2020-11-05,07:00AM,Incyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical Programs,0.0,1.0,0.0,0.0
81,INCY,2020-11-05,06:15AM,Incyte Corp. to Host Earnings Call,0.0,1.0,0.0,0.0
82,INCY,2020-11-04,03:55PM,More than 40 Abstracts from Incytes Oncology Portfolio Accepted for Presentation at the 62nd Annual ASH Virtual Meeting,0.0,0.89,0.11,0.2732
83,INCY,2020-11-04,08:25AM,"Big Drug/Biotech Stock Q3 Earnings on Nov 5: REGN, BMY & More",0.0,1.0,0.0,0.0
84,INCY,2020-11-03,07:31AM,Incyte Corp (INCY) Sees Hammer Chart Pattern: Time to Buy?,0.0,1.0,0.0,0.0
85,INCY,2020-11-02,02:00PM,ACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant® in Rheumatoid Arthritis,0.0,0.647,0.353,0.7184
86,INCY,2020-10-31,10:45AM,EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis,0.126,0.874,0.0,-0.3818
87,INCY,2020-10-31,05:29AM,Point/Counterpoint: The Case for Eli Lilly,0.0,1.0,0.0,0.0
88,INCY,2020-10-30,09:00AM,Incyte Ranked Second Among Science Magazines 2020 Top Biopharma Employers,0.0,0.833,0.167,0.2023
89,INCY,2020-10-30,06:45AM,Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata,0.0,0.833,0.167,0.5574
90,INCY,2020-10-29,12:35PM,Incyte (INCY) Expected to Beat Earnings Estimates: Should You Buy?,0.0,1.0,0.0,0.0
91,INCY,2020-10-29,10:51AM,Incyte (INCY) to Post Q3 Earnings: Will Jakafi Drive Results?,0.0,1.0,0.0,0.0
92,INCY,2020-10-29,08:00AM,Pooled Results from Incytes TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported Quality of Life Assessments,0.0,0.82,0.18,0.5574
93,INCY,2020-10-27,04:29PM,"Novartis Earnings Top, Sales Miss; NVS Stock Falls",0.17,0.638,0.191,0.0516
94,INCY,2020-10-27,04:25PM,"Eli Lilly Earnings Miss, Covid-19 Treatment Fails In Trials",0.386,0.614,0.0,-0.5267
95,INCY,2020-10-20,08:00AM,Incyte to Report Third Quarter Financial Results,0.0,1.0,0.0,0.0
96,INCY,2020-10-08,11:39AM,"Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen",0.0,0.878,0.122,0.2023
97,INCY,2020-10-05,12:48PM,Nimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based Therapeutics,0.0,0.827,0.173,0.3182
98,INCY,2020-09-18,03:48PM,Initial data from a pair of clinical trials may revive interest in arthritis drugs as COVID-19 treatments,0.0,0.722,0.278,0.6597
99,INCY,2020-09-18,12:11PM,"Coronavirus update: Global case tally tops 30 million, and controversial CDC testing guideline changes were reportedly not made by CDC scientists",0.075,0.788,0.137,0.3612
